Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Open access
Clément, Karine, van den Akker, Erica, Argente, Jesús, Bahm, Allison, Chung, Wendy K, Connors, Hillori, De Waele, Kathleen, Farooqi, I Sadaf, Gonneau-Lejeune, Julie, Gordon, Gregory, Kohlsdorf, Katja, Poitou, Christine, Puder, Lia, Swain, James, Stewart, Murray, Yuan, Guojun, Wabitsch, Martin, Kühnen, Peter, Pigeon-Kherchiche, Patricia, Flaus-Furmaniuk, Anna, Bald, Martin, Denzer, Christian, von Schnurbein, Julia, Abawi, Ozair, Blume-Peytavi, Ulrike, Krabusch, Philipp, Mai, Knut, Schnabel, Dirk, Wiegand, Susanna, Flück, Christa E, Schulz, Esther, Voss, Egbert, Bratina, Natasa, Weiss, Katja, Martos-Moreno, Gabriel Á, Danset, Alban, Gougis, Paul, Dubern, Béatrice, Clément, Karine, van den Akker, Erica L.T., Argente, Jesús, Bahm, Allison L, Chung, Wendy K, Connors, Hillori S, De Waele, Kathleen, Farooqi, Ismaa Sadaf, Gonneau-Lejeune, Julie, Gordon, Gregory A, Poitou, Christine, Puder, Lia, Swain, James M, Stewart, Murray W, Yuan, Goujun, Wabitsch, Martin, Kühnen, Peter · 2020 · The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND The melanocortin 4 receptor (MC4R), a component of the leptin-melanocortin pathway, plays a part in bodyweight regulation. Severe early-onset obesity can be caused by biallelic variants in genes that affect the MC4R pathway. We report the results from trials of the MC4R agonist setmelanotide in individuals with severe obesity due to either pro-opiomelanocortin (POMC) deficiency obesity or leptin receptor (LEPR) deficiency obesity. METHODS These single-arm, open-label, multicentre, phase 3 trials were done in ten hospitals across Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK. Participants aged 6 years or older with POMC or LEPR deficiency obesity received open-label setmelanotide for 12 weeks. Participants with at least 5 kg weight loss (or ≥5% if weighing <100 kg at baseline) entered an 8-week placebo-controlled withdrawal sequence (including 4 weeks each of blinded setmelanotide and placebo treatment) followed by 32 additional weeks of open-label treatment. The primary endpoint, which was assessed in participants who received at least one dose of study medication and had a baseline assessment (full analysis set), was the proportion of participants with at least 10% weight loss compared with baseline at approximately 1 year. A key secondary endpoint was mean percentage change in the most hunger score of the 11-point Likert-type scale at approximately 1 year on the therapeutic dose, which was assessed in a subset of participants aged 12 year…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(20)30364-8

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 30 references

Cited by

See all 494

Metadata

Authors
Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., Kohlsdorf, K., Poitou, C., Puder, L., Swain, J., Stewart, M., Yuan, G., Wabitsch, M., Kühnen, P., Pigeon-Kherchiche, P., Flaus-Furmaniuk, A., Bald, M., Denzer, C., von Schnurbein, J., Abawi, O., Blume-Peytavi, U., Krabusch, P., Mai, K., Schnabel, D., Wiegand, S., Flück, C. E., Schulz, E., Voss, E., Bratina, N., Weiss, K., Martos-Moreno, G. Á., Danset, A., Gougis, P., Dubern, B., Clément, K., van den Akker, E. L. T., Argente, J., Bahm, A. L., Chung, W. K., Connors, H. S., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G. A., Poitou, C., Puder, L., Swain, J. M., Stewart, M. W., Yuan, G., Wabitsch, M., & Kühnen, P.
Affiliations
  • Inserm (FR)
  • Universität Ulm (DE)
  • Nutrition et obésité : approches systémiques (FR)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2020-12
Volume
8
Issue
12
Pages
960-970
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3095455148
Cited by
492
References
30
Citations by year
2026: 75 · 2025: 88 · 2024: 100 · 2023: 97 · 2022: 76 · 2021: 55 · 2020: 1
FWCI
29.79
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • HAL (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • Open Access CRIS of the University of Bern
Funders
National Institute for Health and Care Research (NF-SI-0616-10065)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
setmelanotide, melanocortin-4 receptor agonist, morbid obesity, weight loss, hunger, leptin-melanocortin pathway, adverse events, childhood obesity, early-onset obesity, drug safety and efficacy, obesity pharmacotherapy
MeSH terms
Adolescent, Adrenal Insufficiency, Adult, alpha-MSH, Child, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Obesity, Pro-Opiomelanocortin, Prognosis, Anti-Obesity Agents, Receptor, Melanocortin, Type 4, Receptors, Leptin, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30364-8
The paper
Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W. K., Connors, H., De Waele, K., Farooqi, I. S., Gonneau-Lejeune, J., Gordon, G., Kohlsdorf, K., Poitou, C., Puder, L., Swain, J., Stewart, M., Yuan, G., Wabitsch, M., Kühnen, P., Pigeon-Kherchiche, P., . . . Kühnen, P. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30364-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.